Literature DB >> 22882781

Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children.

Ozgur Kizilca1, Rengin Siraneci, Alev Yilmaz, Nevin Hatipoglu, Erkut Ozturk, Aysel Kiyak, Dilek Ozkok.   

Abstract

BACKGROUND: The aim of the present study was to investigate the risk factors of antimicrobial resistance in children with urinary tract infection caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria.
METHODS: A total of 344 patients diagnosed with urinary tract infection (UTI) between January 2008 and December 2009 were enrolled in this retrospective study. Causative microorganisms were ESBL-producing bacteria in 148 patients and non-ESBL-producing bacteria in 196 patients. There was no difference between the two groups regarding distribution of age, sex and length of follow up.
RESULTS: The most frequent causative agent was Escherichia coli, of which 41.4% were ESBL producing. Among Klebsiella species, 53.2% were ESBL producing. The proportion of ESBL-producing bacteria that were resistant to antibiotics was 83.1% for trimethoprim/sulfamethoxazole, 18.2% for nitrofurantoin, 47.3% for quinolones, and 39.9% for aminoglycosides. For non-ESBL-producing bacteria, the resistance rate was 62.2% for trimethoprim/sulfamethoxazole, 4.6% for nitrofurantoin, 9.7% for quinolones, and 9.7% for aminoglycosides. Age <1 year, high UTI recurrence rate, long duration of prophylaxis, use of cephalosporins for prophylaxis, hospitalization within the previous 3 months and clean intermittent catheterization were found to be significant risk factors for ESBL-producing bacteria (P < 0.05). Logistic regression analysis identified age <1 year and high recurrence UTI rate to be independent risk factors, increasing the risk 1.74-fold and 2.25-fold, respectively.
CONCLUSIONS: Recognition of the risk factors for ESBL-producing bacteria may be helpful to determine new policies in the management of UTI. Recurrence of UTI should be prevented especially in the first year of life, and prophylactic cephalosporins should be avoided.
© 2012 The Authors. Pediatrics International © 2012 Japan Pediatric Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882781     DOI: 10.1111/j.1442-200X.2012.03709.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  21 in total

Review 1.  Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.

Authors:  Paul J Lukac; Robert A Bonomo; Latania K Logan
Journal:  Clin Infect Dis       Date:  2015-01-16       Impact factor: 9.079

Review 2.  Antibiotic Resistance in Pediatric Urinary Tract Infections.

Authors:  Jeremy S Stultz; Christopher D Doern; Emily Godbout
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  Risk factors for gentamicin-resistant E. coli in children with community-acquired urinary tract infection.

Authors:  Elsa Roldan-Masedo; Talia Sainz; Almudena Gutierrez-Arroyo; Rosa Maria Gomez-Gil; Estefania Ballesteros; Luis Escosa; Fernando Baquero-Artigao; Ana Méndez-Echevarría
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-29       Impact factor: 3.267

4.  Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children.

Authors:  Hye Sun Hyun; Ji Hye Kim; Myung Hyun Cho; Eujin Park; Il-Soo Ha; Hae Il Cheong; Hee Gyung Kang
Journal:  Pediatr Nephrol       Date:  2019-07-04       Impact factor: 3.714

5.  Comparison of cotrimoxazole vs. second-generation cephalosporins for prevention of urinary tract infections in children.

Authors:  Charalampos Antachopoulos; Maria Ioannidou; Athanasios Tratselas; Elias Iosifidis; Aspasia Katragkou; Paschalis Kadiltzoglou; Konstantinos Kollios; Emmanuel Roilides
Journal:  Pediatr Nephrol       Date:  2016-08-15       Impact factor: 3.714

6.  Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients.

Authors:  Danielle M Zerr; Arianna Miles-Jay; Matthew P Kronman; Chuan Zhou; Amanda L Adler; Wren Haaland; Scott J Weissman; Alexis Elward; Jason G Newland; Theoklis Zaoutis; Xuan Qin
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children.

Authors:  Ayse Karaaslan; Eda Kepenekli Kadayifci; Serkan Atici; Gulsen Akkoc; Nurhayat Yakut; Sevliya Öcal Demir; Ahmet Soysal; Mustafa Bakir
Journal:  Int J Nephrol       Date:  2015-05-27

8.  Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Authors:  Seung Beom Han; Sung Chul Lee; Soo Young Lee; Dae Chul Jeong; Jin Han Kang
Journal:  BMC Infect Dis       Date:  2015-10-13       Impact factor: 3.090

9.  Epidemiology and characteristics of urinary tract infections in children and adolescents.

Authors:  Rima H Hanna-Wakim; Soha T Ghanem; Mona W El Helou; Sarah A Khafaja; Rouba A Shaker; Sara A Hassan; Randa K Saad; Carine P Hedari; Rima W Khinkarly; Farah M Hajar; Marwan Bakhash; Dima El Karah; Imad S Akel; Mariam A Rajab; Mireille Khoury; Ghassan S Dbaibo
Journal:  Front Cell Infect Microbiol       Date:  2015-05-26       Impact factor: 5.293

10.  Third-generation cephalosporin-resistant urinary tract infections in children presenting to the paediatric emergency department.

Authors:  Kristopher T Kang; Karen Ng; Jennifer Kendrick; Peter Tilley; Joseph Ting; Shahrad Rassekh; Srinivas Murthy; Ashley Roberts
Journal:  Paediatr Child Health       Date:  2019-02-05       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.